DNA, D(3'-AMINO-3'-DEOXY-P-THIO)(T-A-G-G-G-T-T-A-G-A-C-A-A), 5'-(O-(2-HYDROXY-3-((1-OXOHEXADECYL)AMINO)PROPYL) HYDROGEN PHOSPHOROTHIOATE)
Glioblastoma
Pediatric Brain Tumor Consortiumnucleic_acidPhase 2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 65/ 100
Competitive context
354 Active assets in the Glioblastoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan Beijing Sanbo Brain Hospital | Phase 2/3 | BBB |
Depatuxizumab Mafodotin AbbVie | Phase 3 | BB |
CARMUSTINE Leland Metheny | Phase 3 | BB |
Irinotecan University of Cincinnati | Phase 3 | BB |
(+)-VINCRISTINE University of Cincinnati | Phase 3 | BB |
View all 50 →
Same molecule, other indications
DNA, D(3'-AMINO-3'-DEOXY-P-THIO)(T-A-G-G-G-T-T-A-G-A-C-A-A), 5'-(O-(2-HYDROXY-3-((1-OXOHEXADECYL)AMINO)PROPYL) HYDROGEN PHOSPHOROTHIOATE) is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →